|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the P50 sensory gating deficits identified in Chinese patients with schizophrenia may not be involved in the psychopathology of the illness.
|
28606770 |
2017 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results show excess allele sharing for multiple markers in 15q11.2-q25, a chromosomal region previously found linked to a decrease in the normal inhibition of the P50 auditory-evoked response to the second of paired stimuli, a decrease associated with schizophrenia.
|
11803532 |
2001 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia.
|
10813805 |
2000 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A paired-stimulus auditory event- related potential paradigm was used to examine P50 sensory gating in 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their first-degree relatives (46 parents and 37 siblings), and 29 normal comparison subjects.
|
12450949 |
2002 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the P50 and N100 decrease correlated with the unaffected subjects' genetic resemblance to schizophrenia patients.
|
16876141 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that the P50 defect is familially associated with schizophrenia.
|
1798824 |
1991 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The defect, a decrease in the normal inhibition of the P50 auditory-evoked response to the second of paired stimuli, is associated with attentional disturbances in schizophrenia.
|
9012828 |
1997 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that, despite the prominent role that P50 abnormalities have played in our understanding of schizophrenia, there is a relative dearth of data examining P50 clinical correlates.
|
16469942 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The locus is unusual in that it was first linked to an endophenotype found in schizophrenia, the P50 deficit, and subsequently to schizophrenia.
|
16843094 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated two neurophysiological endophenotypes of schizophrenia - P50 sensory gating and mismatch negativity in 22q11.2DS subject and evaluated their association with catechol O-methyltransferase (COMT) and proline dehydrogenase (PRODH) genetic variants.
|
23910792 |
2013 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.
|
17349863 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors examined associations between P50 suppression deficits and several core features of schizophrenia to address this gap.
|
29202656 |
2018 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 sensory gating deficits correlate with genetic risk for schizophrenia and constitute a plausible endophenotype for the disease.
|
20102668 |
2011 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence of normalized auditory P50 suppression with acute nicotine in schizophrenia has supported the contention that elevated smoking rates in this disorder may be an attempt to correct a nicotinic receptor pathophysiology that may underly impaired sensory gating in these patients.
|
19961902 |
2010 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As suggested by several studies, abnormal sensory gating measured by the P50 paradigm could be an endophenotype predisposing to schizophrenia.
|
14569275 |
2004 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Auditory P50 gating and hippocampal volume were measured in 16 male and 15 female patients with schizophrenia.
|
30862179 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have used a previously characterized neurophysiological variable, the P50 evoked-auditory response, to search for chromosomal regions that may be of interest in the study of schizophrenia.
|
8399828 |
1993 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined two candidate mechanisms of AVH in patients with BPD, suggested to underlie sensory processing systems that contribute to psychotic symptoms in patients with schizophrenia; sensory gating (P50 ratio and P50 difference) and change detection (mismatch negativity; MMN).
|
31536946 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The nicotinic system has previously been studied in schizophrenia where the neuronal nicotinic acetylcholine receptor alpha 7 subunit gene (CHRNA7) has been implicated in decreased P50 inhibition and attentional disturbances in patients with schizophrenia and in many of their nonschizophrenic relatives.
|
11803515 |
2001 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adult-onset schizophrenia is generally associated with one parent who demonstrates abnormal P50 sensory gating and elevated anticipatory saccades and one parent who is normal on the physiologic measures (i.e., unilineal inheritance).
|
10206241 |
1999 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because P50 sensory gating deficit is a common neurophysiological dysfunction in patients with schizophrenia and schizophrenia spectrum disorders, it is conceivable to hypothesize that the human alpha7 neuronal nicotinic receptor subunit gene might be a susceptible gene for schizophrenia.
|
15531077 |
2004 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Psychopathology of SCZ was rated by the positive and negative syndrome scale (PANSS), while cognitive function and P50 inhibition of subjects were assessed by the MATRICS Consensus Cognitive Battery (MCCB) and the electroencephalography system.
|
31780341 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following reports of SG improvements in low P50 suppressing SCZ patients and healthy participants with the α7 agonist, CDP-choline, this pilot study examined the combined modulatory effect of CDP-choline (500 mg) and galantamine (16 mg), a nAChR positive allosteric modulator and acetylcholinesterase inhibitor, on SG to speech stimuli in twenty-four SCZ patients in a randomized, double-blind and placebo-controlled design.
|
30790597 |
2019 |